F-group (family)
206.1.1.74 Pkinase, PK_Tyr_Ser-Thr
Ligands and drugs
249
Member domains
49
with ligand contacts (≤ 4 Å)
19.7% of members
36
with DrugDomain annotations
14.5% of members
19
with a DrugBank compound
7.6% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 206.1.1.74 belongs to X-group 206 Protein kinase/SAICAR synthase/ATP-grasp, which binds 10.2 ligand superclasses per 20 proteins, broader than 96% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB12010 | — | Fostamatinib | 3 |
| DB05928 | 38O | Dovitinib | 2 |
| DB06080 | — | — | 2 |
| DB06896 | 1FN | 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide | 2 |
| DB08454 | QPP | N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE | 2 |
| DB12147 | — | Erdafitinib | 2 |
| DB01268 | — | Sunitinib | 1 |
| DB02930 | AGS | Adenosine 5'-[gamma-thio]triphosphate | 1 |
| DB04849 | — | — | 1 |
| DB04879 | — | — | 1 |
| DB05075 | — | — | 1 |
| DB05984 | — | RAF-265 | 1 |
| DB06436 | — | Semaxanib | 1 |
| DB06589 | — | — | 1 |
| DB06595 | — | Midostaurin | 1 |
| DB08875 | — | — | 1 |
| DB08896 | — | — | 1 |
| DB08901 | — | Ponatinib | 1 |
| DB12307 | — | Foretinib | 1 |
| DB14840 | — | — | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| IOD | IODIDE ION | 6 |
| A1CNV | methyl 1-[(2,6-dichlorophenyl)methyl]-1H-pyrazole-3-carboxylate | 4 |
| CL | CHLORIDE ION | 4 |
| NAmetal | SODIUM ION | 3 |
| 1FN | 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide | 2 |
| 38O | 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one | 2 |
| A1CNU | cyclopropyl[(4R,5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanone | 2 |
| A1E6R | (3~{S})-~{N}-(cyclopropylmethyl)-5-methyl-4-oxidanylidene-3-[[5-(phenylmethyl)-4~{H}-1,2,4-triazol-3-yl]carbonylamino]-2,3-dihydro-1,5-benzoxazepine-7-carboxamide | 2 |
| A1IX9 | ~{N}-[(1~{S})-1-(2-chloranyl-6-fluoranyl-phenyl)ethyl]-4-fluoranyl-1-[2-fluoranyl-5-(1-methylpyrazol-4-yl)phenyl]carbonyl-piperidine-4-carboxamide | 2 |
| AWJ | (2R)-2-[5-(6-amino-5-{(1R)-1-[2-(1,3-dihydro-2H-1,2,3-triazol-2-yl)-5-fluorophenyl]ethoxy}pyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol | 2 |
| BR | BROMIDE ION | 2 |
| MMW | 2-[(3~{S})-3-azanylpiperidin-1-yl]-4-[[3-(trifluoromethyl)phenyl]amino]pyrimidine-5-carboxamide | 2 |
| O4U | ~{N}-methyl-1-[4-[[[1-methyl-5-(phenylmethyl)pyrazol-3-yl]carbonylamino]methyl]phenyl]benzimidazole-5-carboxamide | 2 |
| QPP | N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE | 2 |
| 1HX | N-[(1S)-1-(2-chloro-6-fluorophenyl)ethyl]-5-cyano-1-methyl-1H-pyrrole-2-carboxamide | 1 |
| 3IU | N-[(3S)-5-methyl-7-[2-(oxan-4-yl)ethynyl]-4-oxidanylidene-2,3-dihydro-1,5-benzoxazepin-3-yl]-5-(phenylmethyl)-4H-1,2,4-triazole-3-carboxamide | 1 |
| 3RJ | N~2~-(1H-benzimidazol-6-yl)-N~4~-(5-cyclobutyl-1H-pyrazol-3-yl)quinazoline-2,4-diamine | 1 |
| 5U5 | 3-[(3~{Z})-3-[[[4-[(dimethylamino)methyl]phenyl]amino]-phenyl-methylidene]-2-oxidanylidene-1~{H}-indol-6-yl]-~{N}-ethyl-prop-2-ynamide | 1 |
| 6UX | 1-[4-[methyl-[2-[(3-sulfamoylphenyl)amino]pyrimidin-4-yl]amino]phenyl]-3-[4-(trifluoromethyloxy)phenyl]urea | 1 |
| 7MY | 7-[(1S)-4-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-2-({3-[(pyrrolidin-1-yl)methyl]phenyl}amino)-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one | 1 |